{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:16:01Z","timestamp":1753355761730},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T00:00:00Z","timestamp":1232668800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Mesothelioma is a highly fatal cancer that is caused by exposure to asbestos fibres. In many populations, the occurrence of mesothelioma is monitored with the use of mortality data from death certification. We examine certified causes of death of patients who have been diagnosed with mesothelioma, and assess the validity of death certification data as a proxy for mesothelioma incidence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We extracted mesothelioma registrations in the South East of England area between 2000 and 2004 from the Thames Cancer Registry database. We retained for analysis 2200 patients who had died at the time of analysis, after having excluded seven dead cases where the causes of death were not known to the cancer registry. The 2200 deaths were classified hierarchically to identify (1) mesothelioma deaths, (2) deaths certified as lung cancer deaths or (3) deaths from unspecified cancer, and (4) deaths from other causes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>87% of the patients had mesothelioma mentioned on the death certificate. 6% had no mention of mesothelioma but included lung cancer as a cause of death. Another 6% had no mention of mesothelioma or lung cancer, but included an unspecified cancer as a cause of death. Lastly, 2% had other causes of death specified on the death certificate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This analysis suggests that official mortality data may underestimate the true occurrence of mesothelioma by around 10%.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-9-28","type":"journal-article","created":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T19:14:06Z","timestamp":1232738046000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Certified causes of death in patients with mesothelioma in South East England"],"prefix":"10.1186","volume":"9","author":[{"given":"Catherine","family":"Okello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Treasure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew G","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Peto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,1,23]]},"reference":[{"key":"1362_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1136\/thx.2007.081430","volume":"63","author":"A Chapman","year":"2008","unstructured":"Chapman A, Mulrennan S, Ladd B, Muers MF: Population-based epidemiology and prognosis of mesothelioma in Leeds, United Kingdom. Thorax. 2008, 63: 435-9. 10.1136\/thx.2007.081430.","journal-title":"Thorax"},{"key":"1362_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/thx.2006.066886","volume":"63","author":"V Mak","year":"2008","unstructured":"Mak V, Davies E, Putcha V, Choodari-Oskooei B, M\u00f8ller H: The epidemiology and treatment of mesothelioma in South East England 1985\u20132002. Thorax. 2008, 63: 160-6. 10.1136\/thx.2006.066886.","journal-title":"Thorax"},{"key":"1362_CR3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjc.6602307","volume":"92","author":"JT Hodgson","year":"2005","unstructured":"Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J: The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer. 2005, 92: 587-93.","journal-title":"Br J Cancer"},{"key":"1362_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/sj.bjc.6603293","volume":"95","author":"DR Camidge","year":"2006","unstructured":"Camidge DR, Stockton DL, Bain M: Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data. Br J Cancer. 2006, 95: 649-52. 10.1038\/sj.bjc.6603293.","journal-title":"Br J Cancer"},{"key":"1362_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1136\/jech.47.6.491","volume":"47","author":"MJ Goldacre","year":"1993","unstructured":"Goldacre MJ: Cause-specific mortality: understanding uncertain tips of the disease iceberg. J Epidemiol Community Health. 1993, 47: 491-6. 10.1136\/jech.47.6.491.","journal-title":"J Epidemiol Community Health"},{"issue":"3","key":"1362_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/ije\/29.3.495","volume":"29","author":"LA Johansson","year":"2000","unstructured":"Johansson LA, Westerling R: Comparing Swedish hospital discharge records with death certificates: implications for mortality statistics. Int J Epidemiol. 2000, 29 (3): 495-502. 10.1093\/ije\/29.3.495.","journal-title":"Int J Epidemiol"},{"key":"1362_CR7","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","volume":"17","author":"MF Muers","year":"2008","unstructured":"Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CMB, Lowry E, Nicholson AG, O'Brien Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MKB, on behalf of the MS01 Trial Management Group: Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma: Results of the Medical Research Council\/British Thoracic Society MS01 multi-centre randomised trial (ISRCTN54469112). Lancet. 2008, 17: 1685-94. 10.1016\/S0140-6736(08)60727-8.","journal-title":"Lancet"},{"key":"1362_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/modpathol.3880018","volume":"13","author":"PM Cury","year":"2000","unstructured":"Cury PM, Butcher DN, Fisher C, Corrin B, Nicholson AG: The value of the mesothelium-associated antibodies, thrombomodulin, cytokeratin 5\/6, calretinin and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Modern Pathology. 2000, 13: 107-12. 10.1038\/modpathol.3880018.","journal-title":"Modern Pathology"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-28.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-9-28\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-28","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-28.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T02:21:22Z","timestamp":1630462882000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-9-28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,23]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1362"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-9-28","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,23]]},"assertion":[{"value":"22 September 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"28"}}